

Mereo BioPharma Group plc
Fourth Floor
One Cavendish Place
London W1G 0QF
United Kingdom

September 29, 2021

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Division of Corporation Finance
Office of Life Sciences
Re: Mereo BioPharma Group plc (the “**Company**”)
Registration Statement on Form F-3
Filed on August 5, 2021
File No. 333-258495

VIA EDGAR

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company respectfully requests that the effectiveness of the registration statement on Form F-3 (File No. 333-258495) of the Company (the “**Registration Statement**”) be accelerated so that the Company’s Registration Statement will become effective at 4:00 p.m., Eastern Time, on September 30, 2021 or as soon thereafter as may be practicable.

The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Mayer Brown LLP, by calling David S. Bakst at (212) 506-2551. The Company hereby authorizes Mr. Bakst to orally modify or withdraw this request for acceleration.

Very truly yours,

MEREO BIOPHARMA GROUP PLC

By: /s/ Denise Scots-Knight

Name: Denise Scots-Knight

Title: Chief Executive Officer

Cc: David S. Bakst
Mayer Brown LLP
Christine Fox
Charles Sermon
Mereo BioPharma Group plc